189 related articles for article (PubMed ID: 35675651)
1. Pt(IV) Prodrugs with Non-Steroidal Anti-inflammatory Drugs in the Axial Position.
Spector DV; Pavlov KG; Akasov RA; Vaneev AN; Erofeev AS; Gorelkin PV; Nikitina VN; Lopatukhina EV; Semkina AS; Vlasova KY; Skvortsov DA; Roznyatovsky VA; Ul'yanovskiy NV; Pikovskoi II; Sypalov SA; Garanina AS; Vodopyanov SS; Abakumov MA; Volodina YL; Markova AA; Petrova AS; Mazur DM; Sakharov DA; Zyk NV; Beloglazkina EK; Majouga AG; Krasnovskaya OO
J Med Chem; 2022 Jun; 65(12):8227-8244. PubMed ID: 35675651
[TBL] [Abstract][Full Text] [Related]
2. New NSAID-Pt(IV) prodrugs to suppress metastasis and invasion of tumor cells and enhance anti-tumor effect in vitro and in vivo.
Song XQ; Ma ZY; Wu YG; Dai ML; Wang DB; Xu JY; Liu Y
Eur J Med Chem; 2019 Apr; 167():377-387. PubMed ID: 30784875
[TBL] [Abstract][Full Text] [Related]
3. Biotinylated Pt(IV) prodrugs with elevated lipophilicity and cytotoxicity.
Spector D; Erofeev A; Gorelkin P; Skvortsov D; Trigub A; Markova A; Nikitina V; Ul'yanovskiy N; Shtil' A; Semkina A; Vlasova K; Zyk N; Majouga A; Beloglazkina E; Krasnovskaya O
Dalton Trans; 2023 Jan; 52(4):866-871. PubMed ID: 36629146
[TBL] [Abstract][Full Text] [Related]
4. Photoinduced Reduction of Novel Dual-Action Riboplatin Pt(IV) Prodrug.
Krasnovskaya OO; Akasov RA; Spector DV; Pavlov KG; Bubley AA; Kuzmin VA; Kostyukov AA; Khaydukov EV; Lopatukhina EV; Semkina AS; Vlasova KY; Sypalov SA; Erofeev AS; Gorelkin PV; Vaneev AN; Nikitina VN; Skvortsov DA; Ipatova DA; Mazur DM; Zyk NV; Sakharov DA; Majouga AG; Beloglazkina EK
ACS Appl Mater Interfaces; 2023 Mar; 15(10):12882-12894. PubMed ID: 36854172
[TBL] [Abstract][Full Text] [Related]
5. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
Chen F; Qin X; Xu G; Gou S; Jin X
Biochem Pharmacol; 2017 Jul; 135():50-68. PubMed ID: 28288821
[TBL] [Abstract][Full Text] [Related]
6. Multi-action Pt(IV) anticancer agents; do we understand how they work?
Gibson D
J Inorg Biochem; 2019 Feb; 191():77-84. PubMed ID: 30471522
[TBL] [Abstract][Full Text] [Related]
7. Biological activity of a series of cisplatin-based aliphatic bis(carboxylato) Pt(IV) prodrugs: how long the organic chain should be?
Zanellato I; Bonarrigo I; Colangelo D; Gabano E; Ravera M; Alessio M; Osella D
J Inorg Biochem; 2014 Nov; 140():219-27. PubMed ID: 25171667
[TBL] [Abstract][Full Text] [Related]
8. Pt(IV) Prodrugs with NSAIDs as Axial Ligands.
Spector D; Krasnovskaya O; Pavlov K; Erofeev A; Gorelkin P; Beloglazkina E; Majouga A
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917027
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative Activity of Pt(IV) Conjugates Containing the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Ketoprofen and Naproxen
Ravera M; Zanellato I; Gabano E; Perin E; Rangone B; Coppola M; Osella D
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31238499
[TBL] [Abstract][Full Text] [Related]
10. Electrochemical Detection of a Novel Pt(IV) Prodrug with the Metronidazole Axial Ligand in the Hypoxic Area.
Spector DV; Erofeev AS; Gorelkin PV; Vaneev AN; Akasov RA; Ul'yanovskiy NV; Nikitina VN; Semkina AS; Vlasova KY; Soldatov MA; Trigub AL; Skvortsov DA; Finko AV; Zyk NV; Sakharov DA; Majouga AG; Beloglazkina EK; Krasnovskaya OO
Inorg Chem; 2022 Sep; 61(37):14705-14717. PubMed ID: 36047922
[TBL] [Abstract][Full Text] [Related]
11. Light-Responsive Pt(IV) Prodrugs with Controlled Photoactivation and Low Dark Toxicity.
Spector D; Bubley A; Zharova A; Bykusov V; Skvortsov D; Ipatova D; Erofeev A; Gorelkin P; Vaneev A; Mazur D; Nikitina V; Melnikov M; Pergushov V; Bunin D; Kuzmin V; Kostyukov A; Egorov A; Beloglazkina E; Akasov R; Krasnovskaya O
ACS Appl Bio Mater; 2024 May; 7(5):3431-3440. PubMed ID: 38697834
[TBL] [Abstract][Full Text] [Related]
12. Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules.
Babu T; Sarkar A; Karmakar S; Schmidt C; Gibson D
Inorg Chem; 2020 Apr; 59(7):5182-5193. PubMed ID: 32207294
[TBL] [Abstract][Full Text] [Related]
13. An Anticancer Pt
Kostrhunova H; Petruzzella E; Gibson D; Kasparkova J; Brabec V
Chemistry; 2019 Apr; 25(20):5235-5245. PubMed ID: 30740808
[TBL] [Abstract][Full Text] [Related]
14. Reprogramming axial ligands facilitates the self-assembly of a platinum(iv) prodrug: overcoming drug resistance and safer in vivo delivery of cisplatin.
Fang T; Ye Z; Wu J; Wang H
Chem Commun (Camb); 2018 Aug; 54(66):9167-9170. PubMed ID: 30062328
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity-boosting of kiteplatin by Pt(IV) prodrugs with axial benzoate ligands.
Margiotta N; Savino S; Marzano C; Pacifico C; Hoeschele JD; Gandin V; Natile G
J Inorg Biochem; 2016 Jul; 160():85-93. PubMed ID: 26775068
[TBL] [Abstract][Full Text] [Related]
16. Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs.
Ravera M; Gabano E; Zanellato I; Bonarrigo I; Alessio M; Arnesano F; Galliani A; Natile G; Osella D
J Inorg Biochem; 2015 Sep; 150():1-8. PubMed ID: 26042542
[TBL] [Abstract][Full Text] [Related]
17. Multi-action platinum(IV) prodrugs conjugated with COX-inhibiting NSAIDs.
Liu X; Wenisch D; Dahlke P; Jordan PM; Jakupec MA; Kowol CR; Liebing P; Werz O; Keppler BK; Weigand W
Eur J Med Chem; 2023 Sep; 257():115515. PubMed ID: 37295160
[TBL] [Abstract][Full Text] [Related]
18. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
[TBL] [Abstract][Full Text] [Related]
19. Interactions between mitochondria-damaging platinum(IV) prodrugs and cytochrome c.
Jayawardhana AMDS; Zheng YR
Dalton Trans; 2022 Feb; 51(5):2012-2018. PubMed ID: 35029256
[TBL] [Abstract][Full Text] [Related]
20. Novel Pt(IV) Prodrugs Displaying Antimitochondrial Effects.
Tabrizi L; Thompson K; Mnich K; Chintha C; Gorman AM; Morrison L; Luessing J; Lowndes NF; Dockery P; Samali A; Erxleben A
Mol Pharm; 2020 Aug; 17(8):3009-3023. PubMed ID: 32628022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
